Double-blind, Randomized, Parallel-group, Dose Ranging, Multicenter Study to Evaluate the Efficacy and Safety of 2.5, 10, 35 and 50 mg AVE 7688 Once Daily, Using 100 mg Losartan-potassium Once Daily as Calibrator, for 12 Months Treatment, in Patients With Mild to Moderate Hypertension.

Trial Profile

Double-blind, Randomized, Parallel-group, Dose Ranging, Multicenter Study to Evaluate the Efficacy and Safety of 2.5, 10, 35 and 50 mg AVE 7688 Once Daily, Using 100 mg Losartan-potassium Once Daily as Calibrator, for 12 Months Treatment, in Patients With Mild to Moderate Hypertension.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Ilepatril; Losartan
  • Indications Hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms RAVEL-1
  • Sponsors Sanofi
  • Most Recent Events

    • 28 Dec 2008 The number of trial centres changed from 22 to 22.
    • 18 Dec 2008 Planned number of patients changed from 1730 to 1940 as reported by ClinicalTrials.gov.
    • 25 Apr 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top